Intravenous Brain-Derived Neurotrophic Factor Reduces Infarct Size and Counterregulates Bax and Bcl-2 Expression After Temporary Focal Cerebral Ischemia
- 1 September 2000
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 31 (9), 2212-2217
- https://doi.org/10.1161/01.str.31.9.2212
Abstract
Background and Purpose —Pretreatment with intraventricular brain-derived neurotrophic factor (BDNF) reduces ischemic damage after focal cerebral ischemia. In this experiment we studied the effect of intravenous BDNF delivered after focal cerebral ischemia on neurological outcome, infarct size, and expression of proapoptotic and antiapoptotic proteins Bax and Bcl-2, respectively. Methods —With the use of the suture occlusion technique, the right middle cerebral artery in rats was temporarily occluded for 2 hours. Thirty minutes after vessel occlusion, BDNF (300 μg/kg per hour in vehicle; n=12) or vehicle alone (n=13) was continuously infused intravenously for 3 hours. After 24 hours the animals were weighed and neurologically assessed on a 5-point scale. The animals were then killed, and brains underwent either 2,3,5-triphenyltetrazolium chloride staining for assessment of infarct volume or paraffin embedding for morphology and immunohistochemistry (Bax, Bcl-2). Results —Physiological parameters (mean arterial blood pressure, P o 2 , P co 2 , pH, body temperature, glucose) and weight revealed no difference between groups. Neurological deficit was improved in BDNF-treated animals versus controls ( P t test). Mean±SD infarct volume was 229.7±97.7 mm 3 in controls and 121.3±80.2 mm 3 in BDNF-treated animals ( P t test). Cortical infarct volume was 155.5±78.5 mm 3 in the placebo group and 69.9±50.2 mm 3 in the BDNF-treated group ( P t test). Subcortical infarct volume was 74.1±30.6 mm 3 in the placebo group and 51.1±26.8 mm 3 in the BDNF-treated group ( P =NS). Bax-positive neurons were significantly reduced in the ischemic penumbra in BDNF-treated animals ( P t test), whereas Bcl-2–positive neurons were significantly increased in this area ( P t test). Conclusions —This study demonstrates a neuroprotective effect of BDNF when delivered intravenously after onset of focal cerebral ischemia. As shown here, one possible mechanism of action of neuroprotection of BDNF after focal ischemia appears to be counterregulation of Bax/Bcl-2 proteins within the ischemic penumbra.Keywords
This publication has 35 references indexed in Scilit:
- Transport of brain-derived neurotrophic factor across the blood–brain barrierNeuropharmacology, 1998
- Delayed Treatment with Intravenous Basic Fibroblast Growth Factor Reduces Infarct Size following Permanent Focal Cerebral Ischemia in RatsJournal of Cerebral Blood Flow & Metabolism, 1995
- Basic Fibroblast Growth Factor Protects against Excitotoxicity and Chemical Hypoxia in Both Neonatal and Adult RatsJournal of Cerebral Blood Flow & Metabolism, 1995
- Role of Bcl‐2 in the Brain‐derived Neurotrophic Factor Survival ResponseEuropean Journal of Neuroscience, 1995
- Temporal Profile of in situ DNA Fragmentation after Transient Middle Cerebral Artery Occlusion in the RatJournal of Cerebral Blood Flow & Metabolism, 1995
- BDNF‐activated Sianal Transduction in Rat Cortical Glial CellsEuropean Journal of Neuroscience, 1995
- Protective effects of BDNF and NT-3 but not PDGF against hypoglycemic injury to cultured striatal neuronsExperimental Neurology, 1995
- Brain‐derived Neurotrophic Factor is a Survival Factor for Cultured Rat Cerebellar Granule Neurons and Protects them Against Glutamate‐induced NeurotoxicityEuropean Journal of Neuroscience, 1993
- trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3Cell, 1991
- The trk Proto-Oncogene Product: a Signal Transducing Receptor for Nerve Growth FactorScience, 1991